Deutsche Bank Reiterates Buy Rating for AstraZeneca (AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by equities researchers at Deutsche Bank in a note issued to investors on Thursday, January 11th. They presently have a GBX 5,700 ($80.04) price objective on the biopharmaceutical company’s stock. Deutsche Bank’s price target suggests a potential upside of 13.19% from the company’s current price.

Several other equities analysts have also weighed in on the stock. Investec raised their price objective on shares of AstraZeneca from GBX 4,900 ($68.81) to GBX 5,500 ($77.24) and gave the company a “buy” rating in a research report on Monday, November 6th. Barclays set a GBX 6,300 ($88.47) price objective on shares of AstraZeneca and gave the company a “buy” rating in a research report on Wednesday, September 13th. Citigroup set a GBX 6,000 ($84.26) price objective on shares of AstraZeneca and gave the company a “buy” rating in a research report on Wednesday, September 13th. Berenberg Bank set a GBX 5,800 ($81.45) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, September 19th. Finally, Jefferies Group reiterated a “hold” rating and issued a GBX 5,100 ($71.62) target price on shares of AstraZeneca in a report on Monday, November 6th. Four investment analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of GBX 5,219 ($73.29).

AstraZeneca (LON:AZN) traded up GBX 150 ($2.11) during trading on Thursday, reaching GBX 5,036 ($70.72). 3,426,966 shares of the company’s stock traded hands, compared to its average volume of 1,600,000. The firm has a market cap of $63,290.00 and a PE ratio of 2,569.39. AstraZeneca has a 52-week low of GBX 4,150 ($58.28) and a 52-week high of GBX 5,520 ($77.52).

WARNING: “Deutsche Bank Reiterates Buy Rating for AstraZeneca (AZN)” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/02/astrazeneca-azn-receives-buy-rating-from-deutsche-bank.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply